Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510747 | 0.98 | KEAP1 (0.54) | KEAP1MAPK1GAANPC1HPGD | |
| SCHEMBL30350850 | 0.98 | KEAP1 (0.54) | KEAP1MAPK1GAANPC1HPGD | |
| SCHEMBL27934132 | 0.83 | MAPK1 (0.74) | KEAP1MAPK1GAANPC1HPGD | |
| SCHEMBL26219177 | 0.80 | MAPK1 (0.70) | KEAP1MAPK1GAANPC1HPGD | |
| SCHEMBL23277135 | 0.78 | ADRB1 (0.57) | ALDH1A1HTTLMNA | |
| SCHEMBL1809115 | 0.78 | ADRB1 (0.62) | HPGDALDH1A1MAPTTSHRHTR6 | |
| SCHEMBL9579357 | 0.78 | MGLL (0.39) | KEAP1MAPK1GAAADRA1AMGLL | |
| SCHEMBL29426367 | 0.78 | ADRA2C (0.60) | MAPK1MAPTEGFRPOLBKMT2A | |
| SCHEMBL172780 | 0.78 | LMNA (0.52) | GAANPC1HPGDL3MBTL1ALDH1A1 | |
| SCHEMBL1810237 | 0.78 | ADRA2C (0.60) | MAPK1MAPTEGFRPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914635-A1 | DIHYDROXY LACTAM BASED POLYMERS, COMPOSITIONS AND APPLICATIONS THEREOF | ISP Investments LLC (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021041866-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020154471-A1 | DIHYDROXY LACTAM BASED POLYMERS, COMPOSITIONS AND APPLICATIONS THEREOF | ISP INVESTMENTS LLC (US) | 2020-07-30 | — | — | WO | disclosed |
| US-10577356-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| US-20190040045-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2019-02-07 | — | — | US | disclosed |
| US-10118914-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2018-11-06 | — | — | US | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-20170166554-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2017-06-15 | — | — | US | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015195486-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2015-12-23 | — | — | WO | disclosed |
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | KEAP1 1098/4885MAPK1 2047/4885GAA 2392/4885 |
| US-20170166554-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | CNR1, CNR2, ARRB1 | KEAP1 910/4885MAPK1 675/4885GAA 3239/4885 |
| US-10577356-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | CNR1, CNR2, ARRB1 | KEAP1 910/4885MAPK1 675/4885GAA 3239/4885 |
| US-10118914-B2 | Beta-arrestin-biased cannabinoid CB1 receptor agonists and methods for making and using them | CNR1, CNR2, ARRB1 | KEAP1 910/4885MAPK1 675/4885GAA 3239/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | KEAP1 1677/4885MAPK1 2746/4885GAA 1413/4885 |
| US-20190040045-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | CNR1, CNR2, ARRB1 | KEAP1 910/4885MAPK1 675/4885GAA 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.